Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net income	$ 969.2	$ 820.2
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	149.7	147.9
Share-based compensation	45.3	52.1
Deferred income taxes	8.9	16.7
Other	(20.2)	(32.9)
Changes in operating assets and liabilities, net:
Accounts receivable	(160.0)	(128.3)
Inventory	(88.6)	(21.5)
Accrued expenses and other current liabilities	(180.8)	(205.5)
Current taxes payable	225.1	154.0
Other changes in operating assets and liabilities, net	14.8	(69.7)
Net cash flows provided by operating activities	963.4	733.0
Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities	1,181.1	373.6
Purchases of marketable securities	(1,914.4)	(323.0)
Acquisitions of business, net of cash acquired	0.0	(198.8)
Purchases of property, plant and equipment	(126.9)	(97.8)
Contingent consideration related to Fumapharm AG acquisition	300.0	250.0
Other	(43.0)	(6.7)
Net cash flows used in investing activities	(1,203.2)	(502.8)
Cash flows from financing activities:
Proceeds from issuance of stock for share-based compensation arrangements	(14.5)	(25.6)
Excess tax benefit from stock options	8.3	66.4
Other	24.6	(11.3)
Net cash flows provided by financing activities	47.4	80.8
Net increase in cash and cash equivalents	(192.4)	311.0
Effect of exchange rate changes on cash and cash equivalents	15.1	(37.8)
Cash and cash equivalents, beginning of the period	1,308.0	1,204.9
Cash and cash equivalents, end of the period	$ 1,130.7	$ 1,478.1